Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: Results of a multicenter study

C. H. Gutierrez-Aguirre, D. Gomez-Almaguer, O. G. Cantu-Rodríguez, O. Gonzalez-Llano, J. C. Jaime-Perez, S. Herena-Perez, C. A. Manzano, R. Estrada-Gomez, M. L. Gonzalez-Carrillo, G. J. Ruiz-Argüelles

Resultado de la investigación: Contribución a una revistaArtículo

22 Citas (Scopus)

Resumen

Using non-myeloablative conditioning, allogeneic hematopoietic stem cell transplantation (HSCT) was conducted in 43 ALL patients in a CR2. The median age of the patients was 19 years. Patients received oral busulfan 4 mg/kg/day for 2 days; i.v. cyclophosphamide 350 mg/m2 day for 3 days; and i.v. fludarabine 30 mg/m2 day for 3 days. Oral cyclosporin A 4 mg/kg was started and methotrexate 5 mg/m2 was delivered on days 1, 3, 5 and 11. The median CD34+ cell dose received was 5.0 × 106/kg. The medium time to achieve a granulocyte count above 0.5 × 109/l was 14 days. Thirteen patients were alive 30-1050 days after the HSCT. The 3-year overall survival rate was 30%. Ten patients (23%) developed acute GVHD, whereas eight patients (18.6%) developed chronic GVHD. Thirty patients died between days 47 and 1050 after the HSCT, most of them (70%) because of an ALL relapse. One hundred-day mortality was 15%, whereas transplant-related mortality was 21%. These results are inferior to those obtained using the same allografting method in other leukemias, probably as a consequence of poor susceptibility to the graft-versus-leukemia effect of the ALL cells beyond first remission as compared with other hematological malignancies.

Idioma originalInglés
Páginas (desde-hasta)535-539
Número de páginas5
PublicaciónBone Marrow Transplantation
Volumen40
N.º6
DOI
EstadoPublicada - 1 sep 2007

Huella dactilar

Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multicenter Studies
Hematopoietic Stem Cell Transplantation
Leukemia
Transplants
Busulfan
Mortality
Homologous Transplantation
Hematologic Neoplasms
Granulocytes
Methotrexate
Cyclophosphamide
Cyclosporine
Survival Rate
Recurrence

Citar esto

Gutierrez-Aguirre, C. H., Gomez-Almaguer, D., Cantu-Rodríguez, O. G., Gonzalez-Llano, O., Jaime-Perez, J. C., Herena-Perez, S., ... Ruiz-Argüelles, G. J. (2007). Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: Results of a multicenter study. Bone Marrow Transplantation, 40(6), 535-539. https://doi.org/10.1038/sj.bmt.1705769
Gutierrez-Aguirre, C. H. ; Gomez-Almaguer, D. ; Cantu-Rodríguez, O. G. ; Gonzalez-Llano, O. ; Jaime-Perez, J. C. ; Herena-Perez, S. ; Manzano, C. A. ; Estrada-Gomez, R. ; Gonzalez-Carrillo, M. L. ; Ruiz-Argüelles, G. J. / Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia : Results of a multicenter study. En: Bone Marrow Transplantation. 2007 ; Vol. 40, N.º 6. pp. 535-539.
@article{beb9f00d6010455b96d37e8b5342ee67,
title = "Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: Results of a multicenter study",
abstract = "Using non-myeloablative conditioning, allogeneic hematopoietic stem cell transplantation (HSCT) was conducted in 43 ALL patients in a CR2. The median age of the patients was 19 years. Patients received oral busulfan 4 mg/kg/day for 2 days; i.v. cyclophosphamide 350 mg/m2 day for 3 days; and i.v. fludarabine 30 mg/m2 day for 3 days. Oral cyclosporin A 4 mg/kg was started and methotrexate 5 mg/m2 was delivered on days 1, 3, 5 and 11. The median CD34+ cell dose received was 5.0 × 106/kg. The medium time to achieve a granulocyte count above 0.5 × 109/l was 14 days. Thirteen patients were alive 30-1050 days after the HSCT. The 3-year overall survival rate was 30{\%}. Ten patients (23{\%}) developed acute GVHD, whereas eight patients (18.6{\%}) developed chronic GVHD. Thirty patients died between days 47 and 1050 after the HSCT, most of them (70{\%}) because of an ALL relapse. One hundred-day mortality was 15{\%}, whereas transplant-related mortality was 21{\%}. These results are inferior to those obtained using the same allografting method in other leukemias, probably as a consequence of poor susceptibility to the graft-versus-leukemia effect of the ALL cells beyond first remission as compared with other hematological malignancies.",
author = "Gutierrez-Aguirre, {C. H.} and D. Gomez-Almaguer and Cantu-Rodr{\'i}guez, {O. G.} and O. Gonzalez-Llano and Jaime-Perez, {J. C.} and S. Herena-Perez and Manzano, {C. A.} and R. Estrada-Gomez and Gonzalez-Carrillo, {M. L.} and Ruiz-Arg{\"u}elles, {G. J.}",
year = "2007",
month = "9",
day = "1",
doi = "10.1038/sj.bmt.1705769",
language = "Ingl{\'e}s",
volume = "40",
pages = "535--539",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

Gutierrez-Aguirre, CH, Gomez-Almaguer, D, Cantu-Rodríguez, OG, Gonzalez-Llano, O, Jaime-Perez, JC, Herena-Perez, S, Manzano, CA, Estrada-Gomez, R, Gonzalez-Carrillo, ML & Ruiz-Argüelles, GJ 2007, 'Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: Results of a multicenter study', Bone Marrow Transplantation, vol. 40, n.º 6, pp. 535-539. https://doi.org/10.1038/sj.bmt.1705769

Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia : Results of a multicenter study. / Gutierrez-Aguirre, C. H.; Gomez-Almaguer, D.; Cantu-Rodríguez, O. G.; Gonzalez-Llano, O.; Jaime-Perez, J. C.; Herena-Perez, S.; Manzano, C. A.; Estrada-Gomez, R.; Gonzalez-Carrillo, M. L.; Ruiz-Argüelles, G. J.

En: Bone Marrow Transplantation, Vol. 40, N.º 6, 01.09.2007, p. 535-539.

Resultado de la investigación: Contribución a una revistaArtículo

TY - JOUR

T1 - Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia

T2 - Results of a multicenter study

AU - Gutierrez-Aguirre, C. H.

AU - Gomez-Almaguer, D.

AU - Cantu-Rodríguez, O. G.

AU - Gonzalez-Llano, O.

AU - Jaime-Perez, J. C.

AU - Herena-Perez, S.

AU - Manzano, C. A.

AU - Estrada-Gomez, R.

AU - Gonzalez-Carrillo, M. L.

AU - Ruiz-Argüelles, G. J.

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Using non-myeloablative conditioning, allogeneic hematopoietic stem cell transplantation (HSCT) was conducted in 43 ALL patients in a CR2. The median age of the patients was 19 years. Patients received oral busulfan 4 mg/kg/day for 2 days; i.v. cyclophosphamide 350 mg/m2 day for 3 days; and i.v. fludarabine 30 mg/m2 day for 3 days. Oral cyclosporin A 4 mg/kg was started and methotrexate 5 mg/m2 was delivered on days 1, 3, 5 and 11. The median CD34+ cell dose received was 5.0 × 106/kg. The medium time to achieve a granulocyte count above 0.5 × 109/l was 14 days. Thirteen patients were alive 30-1050 days after the HSCT. The 3-year overall survival rate was 30%. Ten patients (23%) developed acute GVHD, whereas eight patients (18.6%) developed chronic GVHD. Thirty patients died between days 47 and 1050 after the HSCT, most of them (70%) because of an ALL relapse. One hundred-day mortality was 15%, whereas transplant-related mortality was 21%. These results are inferior to those obtained using the same allografting method in other leukemias, probably as a consequence of poor susceptibility to the graft-versus-leukemia effect of the ALL cells beyond first remission as compared with other hematological malignancies.

AB - Using non-myeloablative conditioning, allogeneic hematopoietic stem cell transplantation (HSCT) was conducted in 43 ALL patients in a CR2. The median age of the patients was 19 years. Patients received oral busulfan 4 mg/kg/day for 2 days; i.v. cyclophosphamide 350 mg/m2 day for 3 days; and i.v. fludarabine 30 mg/m2 day for 3 days. Oral cyclosporin A 4 mg/kg was started and methotrexate 5 mg/m2 was delivered on days 1, 3, 5 and 11. The median CD34+ cell dose received was 5.0 × 106/kg. The medium time to achieve a granulocyte count above 0.5 × 109/l was 14 days. Thirteen patients were alive 30-1050 days after the HSCT. The 3-year overall survival rate was 30%. Ten patients (23%) developed acute GVHD, whereas eight patients (18.6%) developed chronic GVHD. Thirty patients died between days 47 and 1050 after the HSCT, most of them (70%) because of an ALL relapse. One hundred-day mortality was 15%, whereas transplant-related mortality was 21%. These results are inferior to those obtained using the same allografting method in other leukemias, probably as a consequence of poor susceptibility to the graft-versus-leukemia effect of the ALL cells beyond first remission as compared with other hematological malignancies.

UR - http://www.scopus.com/inward/record.url?scp=34548530869&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705769

DO - 10.1038/sj.bmt.1705769

M3 - Artículo

C2 - 17618317

AN - SCOPUS:34548530869

VL - 40

SP - 535

EP - 539

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -